VolitionRX Ltd VNRX

VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.

VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces, as part of the DETECSEPS Consortium, the official launch of the DETECSEPS project on the early detection of sepsis. The Consortium is funded with €6.3 million (~$7.3 million) from the French government.

By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 20

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage

VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations. The multi-national epigenetics firm demonstrated strong momentum across its core diagnostic verticals, including sepsis monitoring, human oncology detection, and companion animal health, positioning the company to address total market opportunities exceeding $2

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.

Moby summary of VolitionRx Limited's Q2 2026 earnings call

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition management will host a conference call tomorrow, August 14 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, August 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter 2026 and to provide a business update. Details of this event can be found below.

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition today announces the publication of the first peer-reviewed paper describing the technology in detail - entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings.

The price target for VolitionRx has been reset from around US$2.20 to roughly US$16.97 per share, marking a major change in how the stock is being framed in recent research. This shift reflects a clear split between analysts who focus on potential execution across the Nu.Q portfolio and others who prefer to keep expectations and assigned value more restrained for now. As you read on, you will see how this evolving narrative may shape the way you track VolitionRx from here. Stay updated as the...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly. The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-w

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.